I'm LongbridgeAI, I can summarize articles.Theravance Biopharma shareholders approved the proposed merger with Zymeworks Inc. at an extraordinary general meeting on September 18, 2026. With 79.14% of shares represented, investors backed the transaction, clearing a key closing condition. Theravance will become a wholly owned subsidiary of Zymeworks, with completion expected around September 23, 2026, subject to remaining conditions.
The latest announcement is out from Theravance Biopharma ( (TBPH) ).
Theravance Biopharma held an extraordinary general meeting on September 18, 2026, at which shareholders voted on proposals tied to a planned merger with Zymeworks Inc., under a June 28, 2026 Merger Agreement that will make Theravance a wholly owned subsidiary of Zymeworks. With 79.14% of outstanding ordinary shares represented, investors approved the core merger proposal, including amendments to Theravance’s governing documents and capital structure, as well as a non-binding advisory vote supporting merger-related executive compensation, clearing a key closing condition for the transaction, which is expected to be completed on or about September 23, 2026, subject to remaining conditions.
The approval of the merger proposals positions Theravance to integrate into Zymeworks’ corporate structure, potentially reshaping its operational autonomy and strategic direction while giving shareholders a path to realize value via the agreed terms. The strong shareholder turnout and decisive support for both the transaction and related compensation packages signal broad investor backing for the deal, though completion remains contingent on satisfaction or waiver of all remaining closing conditions in the merger agreement.
The most recent analyst rating on (TBPH) stock is a Hold
with a $17.00 price target.
To see the full list of analyst forecasts on Theravance Biopharma stock,
see the TBPH Stock Forecast page.
Spark’s Take on TBPH Stock
According to Spark, TipRanks’ AI Analyst, TBPH is a Outperform.
The score is primarily driven by improved TTM profitability, strong current cash generation, and a conservatively levered balance sheet. This is tempered by questions around earnings quality (operating loss vs net income), recent revenue softness, and mixed corporate developments—positive M&A support but negative Phase 3/FDA-readthrough risk. Technicals are mildly supportive but not strongly bullish given the price remains below the 200-day average.
To see Spark’s full report on TBPH stock,
click here.
More about Theravance Biopharma
Theravance Biopharma, Inc. is a biopharmaceutical company, incorporated in the Cayman Islands, focused on developing and commercializing therapies, with its ordinary shares widely held and traded in the public markets. The company operates within the healthcare sector, where strategic transactions such as mergers and acquisitions are a central lever for scaling its pipeline, accessing complementary technologies, and enhancing shareholder value in a competitive biopharma landscape.
Average Trading Volume: 640,158
Technical Sentiment Signal: Buy
Current Market Cap: $884.2M
Find detailed analytics on TBPH stock on TipRanks’ Stock Analysis page.